List view / Grid view
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Data demonstrated that Novacyt’s proprietary technology platform, NOVAprep, and Cepheid’s Xpert HPV test produced highly accurate results...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Nanobiotix, a late clinical-stage nanomedicine company, has appointed Dr Mihail Obrocea as the Head of US Clinical Development and Noel Kurdi as the Director of Investor Relations. In the US, Nanobiotix has filed a new drug application for NBTXR3, as a treatment for prostate cancer and plans to initiate a…
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The company expects to complete the submission of the new drug application (NDA) for vyxeos by early 2017, and will request a priority review...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Click the video to watch the results live from the Nobel Prize Announcements in Chemistry 2016!
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The study met its primary objective which was to determine if 1200mg/day of BC1054 lipid formulated ibuprofen was non-inferior to standard soft gel ibuprofen capsules...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This second alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study, treat ALK-positive non-small cell lung cancer...
4 October 2016 | By Wickham Laboratories
Join us for a free webinar on risks, regulations and determining the best method for your product, 3rd November, 3PM GMT...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The aim of Novartis' plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Click the video to watch the results live from the Nobel Prize Announcements 2016!
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF).
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is...
